filename,source_row_index,headline,qui_tam_score,reason,key_facts,statute_violations,implicated_actors,federal_programs_involved,fraud_type
offlabel_0,1,"Potential off‑label marketing violations involving a drug with 703 adverse event reports and 139 indications, but no evidence of Medicare/Medicaid billing",20,"The record indicates a high volume of adverse events and many indications, suggesting possible off‑label marketing. However, there is no mention of Medicare or Medicaid billing, which is required for a False Claims Act claim. The case may be viable under the FDCA but not as a qui tam action.","703 adverse event reports linked to an unknown drug; 139 distinct indications reported, indicating possible off‑label use; No mention of federal program billing or reimbursement claims",FDCA,Unknown drug manufacturer,,off-label marketing
offlabel_1,2,Potential off‑label prescribing of Lipitor with high adverse event volume that may implicate Medicare billing fraud,60,"The record shows 64 adverse event reports for Lipitor, a drug with known off‑label indications. While the data do not explicitly mention Medicare billing or false claims, the high event volume and indication diversity raise a plausible pattern of off‑label prescribing that could be billed to Medicare. The lack of public disclosure and the need for further verification of billing practices place this case in the medium‑potential range.","64 adverse event reports for Lipitor in FDA FAERS; 4 distinct indications reported, suggesting off‑label use; Serious outcomes include 4 deaths, 1 life‑threatening event, and other severe events; No explicit Medicare billing data provided in the record",False Claims Act; Anti-Kickback Statute,Lipitor,,other
offlabel_2,3,"Potential off‑label marketing of JAKAFI with high adverse event volume and multiple indications, raising FDCA and False Claims Act concerns",85,"The record shows 50 adverse event reports linked to JAKAFI across five indications, indicating a systematic off‑label prescribing pattern. The high event volume and indication diversity suggest a deliberate marketing strategy that could have led to Medicare billing for non‑approved uses, creating strong FDCA and False Claims Act exposure. No public settlement or DOJ announcement is noted, keeping the first‑to‑file window open.","50 adverse event reports for JAKAFI in FDA FAERS; Reports span five distinct indications, none of which are FDA‑approved for JAKAFI; Serious outcomes reported in 5 of the 50 cases, indicating potential patient harm; Record explicitly calls for verification of Medicare coverage and prescribing patterns; No public disclosure or settlement noted",False Claims Act; FDCA,JAKAFI; Healthcare providers prescribing JAKAFI,Medicare; Medicaid,off-label marketing
offlabel_3,4,"Potential off‑label marketing of Humira with high adverse event volume and multiple indications, raising FDCA and False Claims Act concerns",85,"The record shows 31 adverse event reports linked to Humira across 10 indications, indicating a systematic off‑label marketing pattern. The high event volume and indication diversity suggest that the drug was promoted for non‑approved uses, potentially leading to Medicare/Medicaid claims for services paid under false pretenses. No public disclosure or settlement is noted, and the case is recent enough to be within the 6‑year statute of limitations.","31 adverse event reports for Humira in FDA FAERS; 10 distinct indications suggesting off‑label use; Serious outcomes reported in 5 cases (e.g., death, hospitalization); No public settlement or DOJ announcement; Case status listed as unfiled",False Claims Act; FDCA,Humira; Healthcare providers prescribing the drug,Medicare; Medicaid,off-label marketing
offlabel_4,5,"Potential off‑label prescribing scheme for LETAIRIS with 28 adverse events across 12 indications, likely involving Medicare beneficiaries",85,"The record shows a sizable cluster of adverse events (28) linked to 12 different indications, indicating systematic off‑label prescribing. The high event volume and indication diversity suggest a pattern that could involve Medicare beneficiaries, creating a strong False Claims Act opportunity. No public disclosure or settlement is noted, and the case is recent enough to be within the 6‑year statute of limitations.","28 adverse event reports filed with FDA FAERS for LETAIRIS; Reports span 12 distinct indications, indicating off‑label use; Serious outcomes reported in multiple cases (5, 1, 3, 6); No public settlement or DOJ announcement noted; Case status listed as unfiled",False Claims Act; Anti-Kickback Statute,LETAIRIS manufacturer,Medicare,off-label marketing
offlabel_5,6,"Potential off‑label marketing of Depakote ER with high adverse event volume and multiple indications, creating a strong False Claims Act opportunity if Medicare billing is involved",82,"The FAERS data shows a significant number of adverse events (24) linked to 11 different indications, indicating systematic off‑label use. If Medicare claims were submitted for these services, the case would violate both the False Claims Act and the FDCA. No public settlement or DOJ announcement is noted, and the record is recent enough to be within the 6‑year statute of limitations.",24 adverse event reports linked to Depakote ER; 11 distinct indications suggesting off‑label prescribing; No public disclosure or settlement noted; Record marked as unfiled and recent,False Claims Act; FDCA,Depakote ER,Medicare,off-label marketing
offlabel_6,7,"Potential off‑label prescribing scheme for OMNISCAN with 22 adverse events across 13 indications, possibly involving Medicare patients",78,"The record shows a high volume of adverse events and multiple indications for OMNISCAN, suggesting systematic off‑label use. While Medicare involvement is not explicitly stated, the next steps recommend verifying coverage and prescribing patterns, indicating a likely federal program connection. The pattern is not isolated, the damages could be significant, and no public disclosure or settlement has been noted.","22 adverse event reports linked to OMNISCAN; 13 distinct indications, indicating off‑label use; Serious outcomes reported in 5 cases; Case flagged for verification of Medicare coverage and prescribing patterns; No public settlement or DOJ announcement",False Claims Act; Anti‑Kickback Statute; Stark Law,"OMNISCAN manufacturer , prescribing physicians, healthcare facilities",Medicare; Medicaid,off-label marketing
offlabel_7,8,Potential off‑label prednisone prescribing scheme with 18 adverse events across 7 indications that may involve Medicare billing,75,"The FAERS data show a moderate volume of adverse events linked to off‑label use of prednisone across multiple indications, suggesting a systematic pattern.  If Medicare claims were submitted for these off‑label services, the case could trigger both FDCA and False Claims Act liability.  The lack of public disclosure and the need for further verification keep the score high but not at slam‑dunk level.",18 adverse event reports linked to prednisone in FAERS; 5 serious outcomes among the 18 events; 7 distinct indications suggesting off‑label use; No public settlement or DOJ announcement reported,False Claims Act; FDCA,Prednisone,Medicare,off-label marketing / prescribing
offlabel_8,9,Potential off‑label acetaminophen prescribing that may involve Medicare patients,45,"The record indicates 17 adverse event reports for a drug with only one indication, suggesting possible off‑label use. However, there is no explicit mention of Medicare/Medicaid billing or documented claims fraud, and the adverse events alone do not establish a clear False Claims Act violation. The case would need further evidence of federal program involvement and billing patterns before it could be pursued.","17 adverse event reports for Amazon Basic Care Acetaminophen; Only one listed indication, implying potential off‑label use; No documented Medicare/Medicaid billing data provided",False Claims Act; FDCA,Amazon Basic Care Acetaminophen,,off-label marketing
offlabel_9,10,Potential off‑label marketing of MIRENA with limited adverse event data – unlikely to support a new qui tam claim,30,"The record references FDA FAERS adverse event reports for MIRENA, an off‑label use scenario. No Medicare or Medicaid billing information is provided, and the data set is small (16 reports). While off‑label marketing can implicate FDCA violations, it does not constitute a False Claims Act violation unless there is evidence of false billing to federal programs. Therefore the case has limited qui tam potential.","16 FDA FAERS adverse event reports for MIRENA; 1 serious outcome, 3 unknown outcomes; Indication diversity of 2 (suggesting off‑label use); No mention of Medicare/Medicaid billing; Next step recommended: verify Medicare coverage and prescribing patterns",FDCA,MIRENA,,other
offlabel_10,11,Potential off‑label omeprazole prescribing with limited adverse event data – requires verification of Medicare involvement,50,"The record shows 15 adverse event reports for omeprazole, but there is no explicit evidence of Medicare/Medicaid billing or a documented pattern of false claims. The data are limited to FDA FAERS and lack dollar amounts, billing records, or a clear systematic practice. The score reflects the need for additional evidence to determine federal program involvement and potential damages.",15 adverse event reports for omeprazole in FDA FAERS; 5 serious outcomes reported among the 15 events; Indication diversity of 3 suggests possible off‑label use; No Medicare or Medicaid billing data provided,False Claims Act,Good Neighbor Pharmacy,,other
offlabel_11,12,Potential off‑label prescribing of prednisone that may involve Medicare billing and FDCA violations,70,"The record shows 15 adverse event reports linked to prednisone used for 8 different indications, indicating a pattern of off‑label use. If Medicare claims were submitted for these services, the case could violate both the FDCA and the False Claims Act. However, no direct evidence of Medicare billing is provided, so further investigation is required to confirm federal program involvement.",15 adverse event reports involving prednisone; 8 distinct indications suggesting off‑label use; 5 serious outcomes reported among the 15 events; Moderate adverse event volume indicates a potential pattern; Next steps recommend verifying Medicare coverage and prescribing patterns,False Claims Act; FDCA,Prednisone; FDA FAERS database,Medicare,off-label marketing
offlabel_12,13,Potential off‑label marketing of Bayer Genuine Aspirin with limited adverse event data,35,"The record indicates a modest number of adverse events (15) linked to off‑label use, but there is no evidence of Medicare/Medicaid billing or documented false claims. The lack of federal program involvement and the small event volume reduce qui tam viability to a low‑medium range.",15 adverse event reports in FAERS for Bayer Genuine Aspirin; 5 serious outcomes reported among those events; Indication diversity of 2 suggests possible off‑label use; No mention of Medicare/Medicaid billing or claims data,FDCA,Bayer,,off-label marketing
offlabel_13,14,Potential off‑label prescribing of Revlimid with limited adverse event data – unclear federal program involvement,35,"The record only reports 14 FAERS adverse event reports for Revlimid with no explicit mention of Medicare/Medicaid billing or claims. The data suggest possible off‑label use, but without evidence of false claims or federal program billing, the case falls into a low‑priority category.","14 FAERS adverse event reports for Revlimid; 2 serious outcomes, 5 moderate, 1 mild; Indication diversity of 2 suggests possible off‑label use; No Medicare/Medicaid billing data provided",False Claims Act; Anti-Kickback Statute; Stark Law; FDCA,Revlimid,,off-label marketing
offlabel_14,15,Potential off‑label marketing of Rituxan with moderate adverse event volume and unclear Medicare involvement,50,"The record indicates 14 FAERS reports for Rituxan with serious outcomes, suggesting possible off‑label promotion. However, there is no explicit mention of Medicare/Medicaid billing or documented false claims, limiting the strength of a False Claims Act claim. The case remains unfiled and could be pursued if Medicare coverage or billing patterns are later confirmed.","14 FAERS adverse event reports for Rituxan; 5 serious outcomes, 6 serious outcomes reported; Indication diversity of 2 suggests off‑label use; No explicit Medicare/Medicaid billing data provided",False Claims Act; Anti-Kickback Statute,Rituxan,,off-label marketing
offlabel_15,16,Potential off‑label methotrexate marketing scheme with 13 serious adverse events across 8 indications that may have led to false Medicare claims,75,"The record shows a moderate volume of serious adverse events linked to methotrexate used off‑label for 8 different indications, suggesting a systematic marketing practice that could have driven Medicare billing. While no explicit Medicare claims data are provided, the next steps recommend verifying coverage and prescribing patterns, indicating a clear opportunity for further investigation under the False Claims Act.",13 adverse event reports linked to methotrexate; 5 serious outcomes among the 13 events; 8 distinct indications indicating off‑label use; Moderate adverse event volume suggests a pattern rather than isolated incidents; Next steps call for verification of Medicare coverage and prescribing patterns,False Claims Act; Anti‑Kickback Statute,Methotrexate manufacturer,Medicare,off-label marketing
offlabel_16,17,Potential off‑label prescribing of GILENYA with 13 adverse event reports and unclear Medicare involvement,50,"The record indicates 13 adverse event reports for GILENYA, a drug with known off‑label use concerns.  No explicit Medicare/Medicaid billing data or documented false claims are present, and the adverse events alone do not establish a clear pattern of fraudulent billing.  The case is therefore considered medium potential pending further investigation into prescribing patterns and federal program involvement.",13 adverse event reports for GILENYA in FDA FAERS; 5 serious outcomes reported among the 13 events; Indication diversity of 2 suggests possible off‑label use; No Medicare/Medicaid billing data provided in the record,False Claims Act; Anti-Kickback Statute,GILENYA,,other
offlabel_17,18,Potential off‑label etoposide prescribing that may generate false Medicare claims,55,"The record indicates 13 adverse event reports for etoposide, a drug with only one indication listed. While no direct Medicare billing data is provided, the next step explicitly calls for verification of Medicare coverage and prescribing patterns. If off‑label use is widespread among Medicare beneficiaries, it could create a False Claims Act exposure. The lack of documented billing amounts or patterns keeps the score in the medium range.","13 adverse event reports for etoposide in FAERS; 5 serious outcomes among those reports; Only one indication listed for the drug, suggesting off‑label use; Next steps call for verifying Medicare coverage and prescribing patterns",False Claims Act,Unknown provider using etoposide off‑label,,off-label marketing / potential false claims
offlabel_18,19,"Potential off‑label marketing of NIGHTIME SLEEP AID with 13 adverse event reports, but no confirmed Medicare billing evidence",45,"The record indicates a moderate volume of adverse events for an off‑label drug, but there is no explicit mention of Medicare or Medicaid billing. Without evidence that false claims were submitted for federal programs, the case falls into a medium‑low viability range. Further investigation is needed to confirm any federal program involvement and potential damages.",13 adverse event reports filed in FDA FAERS for NIGHTIME SLEEP AID; 5 serious outcomes among those reports; Indication diversity of 1 suggests limited therapeutic use; No mention of Medicare or Medicaid billing in the record,False Claims Act; Anti-Kickback Statute,NIGHTIME SLEEP AID manufacturer,,off-label marketing
offlabel_19,20,Potential off‑label prescribing of lisinopril with 11 adverse event reports – requires verification of Medicare involvement,50,"The record indicates 11 adverse event reports for lisinopril with serious outcomes, suggesting possible off‑label use. However, there is no explicit mention of Medicare/Medicaid billing or documented claims fraud, and the data come from FDA FAERS rather than provider billing records. The case is therefore a medium‑potential opportunity that needs further evidence of federal program involvement and billing patterns.","11 adverse event reports for lisinopril in FDA FAERS; Serious outcomes reported (2, 1, 3, 6); Indication diversity of 3 suggests possible off‑label prescribing; No direct evidence of Medicare/Medicaid billing or claims fraud",False Claims Act; Anti-Kickback Statute,Unknown provider prescribing lisinopril,,other
offlabel_20,21,Potential off‑label marketing of SANDOSTATIN LAR DEPOT with moderate adverse event reports,35,"The record indicates 11 adverse event reports for an off‑label drug, but there is no explicit mention of Medicare/Medicaid billing or federal program involvement. The lack of a clear pattern of false claims and the absence of documented financial impact lower the score to medium‑low. Further investigation is needed to confirm any federal program billing and potential damages.",11 adverse event reports for SANDOSTATIN LAR DEPOT; 5 serious outcomes reported among the 11 events; Indication diversity of 2 suggests possible off‑label use; No explicit Medicare/Medicaid billing data provided,False Claims Act; Anti-Kickback Statute,SANDOSTATIN LAR DEPOT manufacturer,,off-label marketing
offlabel_21,22,Potential off‑label marketing of Clozaril with limited adverse event data – unclear Medicare billing involvement,45,"The record indicates 11 FAERS reports for off‑label use of Clozaril, but there is no explicit mention of Medicare or Medicaid billing. Without evidence that false claims were submitted for federal programs, the case falls into a low‑to‑medium range. Further investigation is needed to confirm whether Medicare claims were filed for these off‑label prescriptions.",11 FAERS adverse event reports for Clozaril; Indication diversity of 1 (suggesting limited therapeutic use); Serious outcomes reported in 3 cases; No explicit Medicare/Medicaid billing data provided,False Claims Act; Anti‑Kickback Statute,Clozaril,,off-label marketing
offlabel_22,23,Potential off‑label prescribing of Allopurinol with limited adverse event data – unclear federal program involvement,35,"The record reports 10 FAERS adverse event reports for Allopurinol, but it does not mention Medicare or Medicaid billing. Without evidence of federal program involvement or documented false claims, the case falls below the 50‑point threshold for a viable qui tam filing. The data are too limited and lack a clear pattern of billing fraud.",10 FAERS adverse event reports for Allopurinol; 5 serious outcomes reported among the 10 events; Indication diversity score of 1 suggests limited therapeutic use; No mention of Medicare/Medicaid billing or claims data,False Claims Act; Anti-Kickback Statute; Stark Law; FDCA,Allopurinol,,other
offlabel_23,24,Potential off‑label marketing of Pradaxa with limited adverse event data and unclear Medicare billing patterns,55,"The record indicates off‑label prescribing of Pradaxa with a modest number of adverse events, but lacks direct evidence of Medicare/Medicaid billing fraud or documented financial loss. The case may involve FDCA violations and could trigger False Claims Act liability if Medicare claims were submitted for off‑label use, but the current evidence is weak and requires further investigation.",10 adverse event reports for Pradaxa in FAERS; Serious outcomes reported in 3 of the 10 cases; Indication diversity of 4 suggests possible off‑label use; No direct Medicare or Medicaid billing data provided,FDCA,Pradaxa manufacturer: Allergan/AbbVie,,off-label marketing
offlabel_24,25,Potential off‑label prescribing of cyclophosphamide that may trigger false claims for Medicare billing,55,"The record shows a pattern of cyclophosphamide prescribed for six different indications, with nine adverse events and multiple serious outcomes. While the data come from FDA FAERS and do not yet confirm Medicare billing, the diversity of indications suggests possible off‑label use that could be billed to federal programs. The case is unfiled and no public settlement or DOJ announcement has been noted, but further evidence of Medicare claims is required to confirm a viable False Claims Act claim.","Cyclophosphamide prescribed for six distinct indications; Nine adverse events reported, five serious outcomes; Off‑label use may be billed to Medicare/Medicaid if not medically justified; Record originates from FDA FAERS, indicating potential regulatory concern",False Claims Act; FDCA,Unnamed prescribing provider,Medicare; Medicaid,off-label marketing
offlabel_25,26,Potential off‑label marketing of furosemide with limited adverse event data,30,"The record indicates a small number of adverse events and no explicit Medicare/Medicaid billing data. The only hint of federal program involvement is a suggestion to verify coverage, which is insufficient for a strong qui tam case. The limited adverse event count and lack of documented billing fraud keep the score low.",Drug: furosemide; 9 adverse events reported in FAERS; 2 serious outcomes among those events; Indication diversity of 4 suggests possible off‑label use; No Medicare/Medicaid billing data provided,False Claims Act; FDCA,FDA FAERS database,,off-label marketing
offlabel_26,27,Potential off‑label marketing of Plavix with limited evidence of Medicare involvement,30,The record indicates possible off‑label use of Plavix but provides no evidence that Medicare or Medicaid claims were submitted for these uses. The limited adverse event data and lack of billing documentation keep the case in the low‑priority range.,Plavix was reported in 9 FAERS cases with serious outcomes; Indication diversity of 3 suggests possible off‑label uses; No Medicare/Medicaid billing data provided,False Claims Act; FDCA,Plavix,,off-label marketing
offlabel_27,28,Potential off‑label marketing of Ventrixyl with limited evidence of Medicare involvement,30,"The record indicates off‑label use of Ventrixyl but provides no evidence that Medicare or Medicaid claims were submitted for these prescriptions. The lack of federal program mention and the absence of documented billing patterns keep the score low, though further investigation into prescribing data could raise the potential.","Drug Ventrixyl reported in FDA FAERS with 9 adverse events; 2 serious outcomes, 1 death, 3 hospitalizations, 6 life‑threatening events; Indication diversity of 4 suggests off‑label use; No mention of Medicare/Medicaid billing or claims data",False Claims Act; Anti-Kickback Statute,Ventrixyl manufacturer,,off-label marketing
offlabel_28,29,Off‑label prescribing of Lyrica with limited adverse event data – low qui tam potential,30,"The record only indicates off‑label use of Lyrica and a small number of adverse events reported to FAERS. No explicit Medicare/Medicaid billing or claims data are provided, and the adverse event count is low. The lack of federal program involvement and limited evidence keeps the score at 30.",FAERS record lists 8 adverse events for Lyrica; 5 serious outcomes reported among those events; Indication diversity of 4 suggests off‑label use; No Medicare or Medicaid billing data provided,False Claims Act,Unknown prescriber / provider,,other
offlabel_29,30,Potential off‑label prescribing of lorazepam with limited evidence of Medicare involvement,30,The record indicates off‑label use of lorazepam but provides no evidence that Medicare or Medicaid claims were submitted. The limited adverse event data and lack of billing information keep the case in the low‑priority range.,"Lorazepam was reported in 8 FAERS cases with serious outcomes.; Indication diversity is only 2, suggesting limited therapeutic use.; No Medicare or Medicaid billing data are provided.",False Claims Act; Anti-Kickback Statute,Lorazepam,,off-label marketing
offlabel_30,31,Potential off‑label marketing of Metformin Hydrochloride with limited adverse event data,30,"The record indicates a small number of adverse events and no explicit mention of Medicare/Medicaid billing or false claims. The only hint is a need to verify off‑label prescribing, which alone does not meet the threshold for a strong qui tam opportunity. The case is likely too weak and may be outside federal program coverage.",Metformin Hydrochloride reported in FDA FAERS with 8 adverse events; 5 serious outcomes among the reports; Indication diversity of 3 suggests possible off‑label use; No Medicare or Medicaid billing data provided,False Claims Act; Anti-Kickback Statute; Stark Law; FDCA,,,off-label marketing
offlabel_31,32,Potential off‑label marketing of Lasix with limited adverse event data,30,"The record indicates off‑label use of Lasix but provides no evidence of Medicare/Medicaid billing, no documented false claims, and only a small number of adverse events. The lack of federal program involvement and the absence of a clear billing pattern keep the score low.",8 adverse events reported for Lasix in FAERS; 2 serious outcomes among those events; Indication diversity of 2 suggests possible off‑label use; No Medicare or Medicaid billing data provided,False Claims Act; Anti-Kickback Statute; Stark Law; FDCA,Lasix,,off-label marketing
offlabel_32,33,Potential off‑label marketing of AUBAGIO with limited evidence of Medicare involvement,30,"The record indicates possible off‑label use of AUBAGIO but provides no evidence of Medicare/Medicaid billing, specific dollar amounts, or a documented pattern. The limited adverse event data and single indication diversity suggest a low likelihood of a strong False Claims Act claim.","AUBAGIO reported in FDA FAERS with 7 adverse events; 2 serious outcomes among the events; Only one indication reported, suggesting possible off‑label use; No Medicare or Medicaid billing data provided",False Claims Act; Anti-Kickback Statute,AUBAGIO,,off-label marketing
offlabel_33,34,Potential off‑label prescribing of Simvastatin with limited adverse event data,30,"The record indicates a small number of adverse events and only two indications, suggesting limited evidence of widespread off‑label use. No Medicare/Medicaid billing data or documented financial gain are provided, and the case is not recent enough to guarantee a strong pattern. The score reflects low viability for a qui tam filing.","Simvastatin reported in FDA FAERS with 7 adverse events; 2 serious outcomes among the 7 events; Only 2 distinct indications noted, implying possible off‑label use; No billing or financial data provided",False Claims Act; FDCA,Simvastatin,,off-label marketing
offlabel_34,35,Potential off‑label prescribing of EFFEXOR XR with limited adverse event data,30,"The record indicates off‑label use of EFFEXOR XR but provides no evidence of Medicare/Medicaid billing, no documented pattern of false claims, and only a small number of adverse events. The lack of federal program involvement and the absence of clear billing fraud keep the score low.","Drug: EFFEXOR XR reported in FDA FAERS; 7 adverse events recorded, 3 serious outcomes; Indication diversity of 2 suggests possible off‑label use; No Medicare/Medicaid billing data provided",False Claims Act; Anti-Kickback Statute,Unknown prescriber; Pharmaceutical manufacturer of EFFEXOR XR,,off-label marketing
offlabel_35,36,Potential off‑label marketing of ibuprofen with limited adverse event data,30,"The record only indicates a small number of adverse events and no explicit Medicare/Medicaid billing or claims data. The lack of documented federal program involvement, the low dollar impact implied by six events, and the absence of a clear systematic pattern keep this case in the low‑priority range.","IBUPROFEN listed in FDA FAERS with 6 adverse events; 2 serious outcomes, 1 unknown, 6 total events; 3 indication diversity points to possible off‑label use; No Medicare/Medicaid billing data provided",False Claims Act; FDCA,IBUPROFEN manufacturer,,off-label marketing
offlabel_36,37,Off‑label clonazepam prescribing with limited adverse event data – low qui tam potential,30,"The record only notes off‑label use of clonazepam and a small number of adverse events. No explicit Medicare/Medicaid billing or documented false claims are mentioned, and the data set is too limited to establish a systematic fraud pattern. The case falls into the low‑priority range.",Drug: clonazepam; 6 adverse events reported in FAERS; 5 serious outcomes among those events; Indication diversity of 2 (suggesting possible off‑label use); No Medicare/Medicaid billing data provided,False Claims Act,,,other
offlabel_37,38,Potential off‑label prescribing of ceftriaxone with limited adverse event data,30,"The record indicates only six adverse events and a single indication, with no explicit Medicare/Medicaid billing or documented false claims. The limited data and lack of a clear pattern reduce viability for a qui tam action.","Six adverse events reported in FAERS for ceftriaxone; Only one indication recorded, suggesting possible off‑label use; No Medicare or Medicaid billing information provided",False Claims Act; FDCA,Ceftriaxone manufacturer,,off-label marketing
offlabel_38,39,Potential off‑label prescribing of Metronidazole with limited adverse event data,30,"The record indicates a small number of adverse events and only one indication, suggesting limited scope. No explicit Medicare/Medicaid billing or documented fraud pattern is present, and the data come from FDA FAERS rather than provider claims. The case falls into the low‑priority range and would require substantial additional evidence before a qui tam filing could be considered.","Metronidazole reported in 6 FAERS cases; 2 serious outcomes, 1 death, 6 serious events overall; Only one indication reported in the FAERS data set; No Medicare or Medicaid billing information provided",False Claims Act; FDCA,Metronidazole,,off-label marketing
offlabel_39,40,Potential off‑label marketing of dexamethasone with limited adverse event data,30,"The record indicates a small number of adverse events and no explicit Medicare/Medicaid billing data. The only hint is off‑label use, which alone does not meet the threshold for a strong False Claims Act case. The limited evidence and lack of documented billing fraud keep the score low.",Drug: dexamethasone; 6 adverse events reported in FAERS; 1 serious outcome among those events; 3 different indications noted (suggesting off‑label use); No Medicare/Medicaid billing data provided,False Claims Act; Anti-Kickback Statute,,,off-label marketing
offlabel_40,41,Potential off‑label marketing of ABRAXANE with limited adverse event data,30,"The record indicates a small number of adverse events and no explicit Medicare/Medicaid billing data. The only hint is to verify off‑label prescribing, which may raise False Claims Act concerns if Medicare claims were submitted for non‑approved indications. However, the evidence is weak and the case lacks a documented billing pattern or significant dollar amounts.",ABRAXANE reported in FDA FAERS with 6 adverse events; 5 serious outcomes among the 6 events; Indication diversity of 4 suggests possible off‑label use; No Medicare/Medicaid billing data provided,False Claims Act; FDCA,ABRAXANE,,off-label marketing
offlabel_41,42,Potential off‑label marketing of SDAMLO with limited evidence of Medicare involvement,30,"The record only indicates six adverse event reports and a few serious outcomes for SDAMLO, with no explicit mention of Medicare or Medicaid billing. The lack of federal program involvement and the absence of documented billing fraud keep the score low, though further investigation into prescribing patterns could uncover additional evidence.",Six adverse event reports filed in FDA FAERS for SDAMLO; Two serious outcomes among the six events; Indication diversity of 2 suggests possible off‑label use; No Medicare or Medicaid billing data provided,False Claims Act; FDCA,SDAMLO,,off-label marketing
offlabel_42,43,Potential off‑label marketing of bisoprolol with limited adverse event data,30,"The record indicates a small number of adverse events and only one indication, suggesting possible off‑label promotion. However, there is no explicit evidence of Medicare/Medicaid billing fraud, no documented pattern of false claims, and the data set is too limited for a strong qui tam case. The case remains unfiled but would need substantial additional evidence to move forward.","Bisoprolol reported in FDA FAERS with 6 adverse events; Only one indication recorded, implying possible off‑label use; No Medicare or Medicaid billing information provided; Case status listed as unfiled",FDCA,Bisoprolol,,off-label marketing
offlabel_43,44,Potential off‑label marketing of REBIF with limited adverse event data – requires confirmation of Medicare/Medicaid billing,30,"The record only indicates adverse events reported to FAERS for an off‑label use of REBIF.  No explicit Medicare or Medicaid billing information is provided, and the adverse event count is small (6).  Without evidence of federal program involvement or a documented billing pattern, the case falls into the low‑priority range.",REBIF reported in FAERS for 6 adverse events; 2 serious outcomes among those events; Indication diversity of 3 suggests off‑label use; No Medicare/Medicaid billing data provided,False Claims Act; Anti-Kickback Statute,REBIF,,off-label marketing
offlabel_44,45,Potential off‑label prescribing of EXJADE across multiple indications with serious adverse events,55,"The record shows six adverse events, five of which were serious, linked to EXJADE prescribed for five different indications. While no explicit Medicare/Medicaid billing data is provided, the diversity of indications and serious outcomes suggest a pattern that could involve federal program claims if off‑label use was billed. The lack of public disclosure and the need for further verification keep this case in the medium‑potential range.","EXJADE was reported in six FAERS cases with five serious outcomes; The drug was used for five distinct indications, indicating off‑label prescribing; No public settlement or DOJ announcement has been made; The case is currently listed as unfiled",False Claims Act; FDCA,EXJADE manufacturer,,off-label marketing
offlabel_45,46,Potential off‑label marketing of oxycodone with limited adverse event data,30,"The record only indicates a small number of adverse events reported to FAERS for oxycodone, with no explicit mention of Medicare/Medicaid billing or false claims. The lack of federal program involvement and the minimal event count keep the score low, though off‑label marketing could still raise FDCA concerns.",FAERS record for oxycodone with 6 adverse events; 5 serious outcomes reported among the events; Indication diversity of 3 suggests varied uses; No Medicare/Medicaid billing data provided,FDCA,Unknown manufacturer or prescriber,,off-label marketing
offlabel_46,47,Potential off‑label prescribing of pantoprazole with limited evidence of Medicare involvement,30,"The record only indicates off‑label use of pantoprazole and a small number of adverse events reported to FAERS. No explicit Medicare or Medicaid billing data are provided, and the case lacks a documented pattern of false claims. The score reflects low viability for a qui tam action under the current information.",Pantoprazole sodium was reported in 6 FAERS adverse event cases; 2 serious outcomes were recorded among the reports; Indication diversity of 3 suggests varied off‑label uses; No Medicare or Medicaid billing data are cited in the record,False Claims Act; Anti-Kickback Statute,Unknown prescriber or pharmacy,,off-label marketing
offlabel_47,48,Off‑label levothyroxine use with limited adverse event data – low qui tam potential,30,"The record only notes six adverse events and two serious outcomes for levothyroxine, with no explicit mention of Medicare/Medicaid billing or false claims. Off‑label marketing alone does not satisfy the False Claims Act unless tied to federal program billing, so the case is unlikely to meet first‑to‑file requirements.",Six adverse events reported in FDA FAERS for levothyroxine; Two serious outcomes among those events; Indication diversity of 2 suggests limited therapeutic use; No Medicare or Medicaid billing data provided,False Claims Act; Anti-Kickback Statute; Stark Law; FDCA,,,other
offlabel_48,49,Potential off‑label marketing of AMPYRA with limited adverse event data – low qui tam viability,30,"The record only indicates a small number of adverse events reported to FAERS for AMPYRA and suggests off‑label use. No Medicare/Medicaid billing or claims data are mentioned, and the adverse event count is low (6). The lack of federal program involvement and limited evidence keeps the score at 30, indicating a low priority for qui tam action.",AMPYRA reported in FAERS with 6 adverse events; 2 serious outcomes among the reports; Indication diversity of 2 suggests possible off‑label use; No Medicare/Medicaid billing data provided,False Claims Act; Anti-Kickback Statute,AMPYRA,,off-label marketing
offlabel_49,50,Potential off‑label marketing of TEGRETOL with limited adverse event data,30,"The record indicates only six adverse events and two indications, with no explicit Medicare/Medicaid billing or documented false claims. The limited data and lack of a clear federal program link keep the score low, though further investigation into prescribing patterns could raise the potential.",Drug: TEGRETOL (generic of erlotinib); 6 adverse events reported in FAERS; 2 distinct indications noted; No mention of Medicare/Medicaid billing or claims data,False Claims Act; Anti-Kickback Statute,TEGRETOL manufacturer,,off-label marketing
offlabel_50,51,Potential off‑label prescribing of 7030 Calcium Premium with limited adverse event data,30,"The record only indicates a small number of adverse events reported to FAERS and notes the need to verify Medicare coverage. No explicit evidence of false claims, systematic billing fraud, or federal program involvement is provided, and the data set is too limited for a strong qui tam case.",Drug name: 7030 Calcium Premium; 6 adverse events reported in FAERS; 2 serious outcomes among those events; Indication diversity: 1 (suggesting limited therapeutic use); Next step suggested: verify Medicare coverage and prescribing patterns,False Claims Act; Anti-Kickback Statute,,,off-label marketing
offlabel_51,52,Potential off‑label marketing of ONFI with limited adverse event data,30,The record only indicates a small number of adverse events and suggests off‑label use; no explicit Medicare/Medicaid billing or documented fraud pattern is present. The score reflects the low likelihood of a viable qui tam claim under current information.,Drug name: ONFI; 6 adverse events reported in FAERS; 5 of 6 events were serious; Indication diversity: 3 different indications; No Medicare/Medicaid billing data provided,FDCA,ONFI,,off-label marketing
offlabel_52,53,Potential off‑label prescribing of Vitamin D with no clear Medicare/Medicaid billing evidence,30,"The record only indicates adverse events from off‑label use of Vitamin D and does not mention Medicare or Medicaid billing. Without evidence of federal program involvement, the case falls into the low‑priority range per the scoring framework.","5 adverse events reported in FAERS for Vitamin D; All 5 events were serious (outcomes 5, 3, 6); Indication diversity of 2 suggests possible off‑label use; No mention of Medicare or Medicaid billing in the record",False Claims Act; FDCA,Vitamin D manufacturer,,off-label marketing
offlabel_53,54,Potential off‑label prescribing of potassium chloride with limited adverse event data,30,"The record indicates only five adverse events and no explicit Medicare/Medicaid billing information. The data are too sparse to establish a clear pattern of false claims, and the adverse events alone do not prove fraudulent billing. The case is therefore low priority for a qui tam filing.",Drug: potassium chloride; 5 adverse events reported in FAERS; 2 serious outcomes among the 5; Indication diversity of 3 (suggests varied uses); No Medicare/Medicaid billing data provided,False Claims Act,,,other
offlabel_54,55,Potential off‑label marketing of ranitidine with limited evidence of Medicare involvement,30,The record indicates off‑label use of ranitidine but provides no evidence that Medicare or Medicaid claims were submitted for these services. The limited adverse event count and lack of documented billing patterns keep the case in the low‑priority range.,"Ranididine was reported in 5 FAERS adverse events; 2 serious outcomes, 1 death, and 3 other serious outcomes were recorded; Indication diversity of 2 suggests possible off‑label use; No Medicare or Medicaid billing data provided",False Claims Act; FDCA,Ranididine manufacturer,,off-label marketing
offlabel_55,56,Potential off‑label marketing of JANUVIA with limited evidence of Medicare involvement,30,"The record only indicates adverse events reported to FAERS for JANUVIA and suggests a need to verify Medicare coverage. No explicit Medicare/Medicaid billing or claims data are provided, and the case lacks a documented pattern of false claims. The score reflects the low likelihood of a viable qui tam action under current information.","FAERS record for JANUVIA with 5 adverse events; All serious outcomes reported (5, 1, 3, 6); Indication diversity of 2 suggests possible off‑label use; No Medicare/Medicaid billing data provided",False Claims Act; Anti-Kickback Statute,JANUVIA,,off-label marketing
offlabel_56,57,Potential off‑label prescribing of Citalopram with limited adverse event data,30,"The record indicates only five adverse events and two indications, with no explicit Medicare/Medicaid billing data or documented false claims. The limited scope and lack of evidence for systematic fraud keep the score low.","Citalopram reported in FDA FAERS with 5 adverse events; Serious outcomes recorded for 2, 1, 3, and 6 patients; Only two indication categories noted; No Medicare or Medicaid billing information provided",FDCA,Citalopram,,off-label marketing
offlabel_57,58,Potential off‑label prescribing of Lansoprazole with no clear Medicare/Medicaid billing evidence,35,"The record indicates five adverse events for Lansoprazole but provides no evidence of Medicare or Medicaid billing, no documented pattern of false claims, and no mention of a corporate policy. The lack of federal program involvement keeps the score low, though the presence of serious outcomes suggests a need for further investigation.","Five adverse events reported for Lansoprazole in FAERS; All serious outcomes recorded (5, 1, 3, 6); Indication diversity noted as 1 (suggesting limited therapeutic use); No mention of Medicare/Medicaid billing or claims; Next step recommended: verify Medicare coverage and prescribing patterns",False Claims Act,BASIC CARE LANSOPRAZOLE,,other
offlabel_58,59,Potential off‑label marketing of DIOVAN with limited adverse event data,30,"The record indicates only five adverse events with no indication diversity, suggesting a very small sample and unclear federal program involvement. No Medicare/Medicaid billing data are provided, and the case is not yet verified for federal program use. The limited evidence and lack of documented billing fraud keep the score low.","Drug: DIOVAN reported in FDA FAERS; 5 adverse events recorded, all serious outcomes; Indication diversity: 0 (no documented therapeutic indication); Case status listed as unfiled; Next steps recommend verifying Medicare coverage and prescribing patterns",False Claims Act; FDCA,DIOVAN,,off-label marketing
offlabel_59,60,Potential off‑label prescribing of Metoprolol with limited adverse event data,30,"The record indicates only five adverse events and two indications, with no explicit Medicare/Medicaid billing data or documented pattern of fraud. The information is too sparse to support a strong False Claims Act claim, and the score reflects low viability.","Metoprolol listed in FDA FAERS with 5 adverse events; Serious outcomes reported for 2, 1, 3, and 6 patients; Indication diversity noted as 2; No Medicare or Medicaid billing information provided",FDCA,Metoprolol,,off-label marketing
offlabel_60,61,Off‑label marketing of Neurontin with limited adverse event data – low qui tam potential,30,"The record only indicates a small number of adverse events and no explicit Medicare/Medicaid billing or claims data. Off‑label marketing alone does not trigger the False Claims Act unless it leads to false federal claims, and no evidence of such claims is provided. The case falls into the low‑priority range.",Drug: Neurontin (gabapentin); 5 adverse events reported in FAERS; No mention of Medicare or Medicaid billing; Indication diversity score of 4 suggests some off‑label use,False Claims Act; Anti-Kickback Statute,Neurontin,,off-label marketing
offlabel_61,62,Potential off‑label marketing of Prozac with limited adverse event data,30,"The record indicates only five adverse events and no explicit Medicare/Medicaid billing or claims data. The information is too sparse to establish a clear pattern of false claims, and the adverse event count is low. The case falls into the low‑priority range.","Drug: Prozac (fluoxetine); 5 adverse events reported in FAERS; Serious outcomes listed as 5, 1, 6 (no context); Indication diversity of 2; No Medicare/Medicaid billing information provided",FDCA,Prozac,,off-label marketing
offlabel_62,63,Potential off‑label marketing of YAZ with limited adverse event data,30,"The record only indicates a small number of adverse events and one indication, with no explicit Medicare/Medicaid billing or documented false claims. The lack of federal program involvement and the minimal dollar impact keep the score low.","YAZ reported in FDA FAERS with 5 adverse events; 2 serious outcomes, 1 unknown; Only one indication listed (indication diversity = 1); No mention of Medicare/Medicaid billing or claims; Next steps suggest verifying coverage and prescribing patterns",FDCA,YAZ,,off-label marketing
offlabel_63,64,Potential off‑label marketing of Soliris with limited evidence of Medicare involvement,30,"The record indicates off‑label use of Soliris but provides no evidence that Medicare or Medicaid claims were submitted for these uses. The limited adverse event count and single indication diversity suggest a very small, isolated pattern that does not meet the threshold for a strong qui tam opportunity.","Soliris reported in FDA FAERS with 5 adverse events; Only one indication recorded, suggesting limited use; No mention of Medicare or Medicaid billing in the record",False Claims Act; FDCA,Soliris,,off-label marketing
cms_leie_raw_row_0,65,No evidence of federal healthcare program billing or fraud in the provided record,5,"The record describes a marketing service company operating a sober home with no mention of Medicare, Medicaid, or other federal health programs. There is no indication of billing activity, fraudulent behavior, or any pattern that would trigger a False Claims Act claim. The lack of federal program involvement and absence of any fraud indicators result in a very low viability score.","Business name: #1 MARKETING SERVICE, INC; Specialty listed as SOBER HOME (non‑clinical service); No mention of Medicare, Medicaid, or other federal health programs; Exclusion type 1128a1 (non‑covered service) with exclusion date 2020-03-19; No billing or claim data provided",,"#1 MARKETING SERVICE, INC",,other
cms_leie_raw_row_1,66,Home health agency excluded from Medicare; no evidence of unfiled False Claims Act violations,20,"The record only indicates that 1 BEST CARE, INC is a home health agency excluded from Medicare (EXCLTYPE 1128b5). No billing data, no mention of Medicare/Medicaid claims, or fraudulent activity is provided. The exclusion itself does not constitute a qui tam opportunity unless additional evidence of false claims exists.","Business name: 1 BEST CARE, INC; Specialty: Home Health Agency; NPI: 0000000000; Exclusion type: 1128b5 (Medicare exclusion); No billing or claim information provided",False Claims Act,"1 BEST CARE, INC",,other
cms_leie_raw_row_2,67,Pharmacy excluded from Medicare Part B – no evidence of unfiled False Claims Act violations,5,"The record indicates that 101 First Care Pharmacy Inc. was excluded from Medicare Part B (EXCLTYPE 1128b8) as of March 2022. No billing data, claims, or allegations of fraudulent activity are provided, and exclusion itself does not constitute a False Claims Act violation. Without evidence of false claims or Medicare billing, the case is unlikely to support a qui tam action.","Business name: 101 First Care Pharmacy Inc.; NPI: 1972902351; Exclusion type: 1128b8 (Medicare Part B exclusion); Exclusion date: March 20, 2022; No billing or claim information provided",False Claims Act,101 First Care Pharmacy Inc.,,other
cms_leie_raw_row_3,68,Excluded pharmacy with no evidence of federal program billing – not a viable qui tam opportunity,5,"The record identifies a pharmacy that is excluded from Medicare/Medicaid billing under 1128a1. No mention of Medicare or Medicaid claims, no dollar amounts, and no indication of fraudulent activity. The lack of federal program involvement places it in the ""not viable"" category.",Business name: 14 Lawrence Ave Pharmacy; Exclusion type: 1128a1 (pharmacy excluded from Medicare/Medicaid); No mention of Medicare or Medicaid billing; No dollar amounts or patterns provided,,14 Lawrence Ave Pharmacy,,other
cms_leie_raw_row_4,69,DME company with no evidence of Medicare/Medicaid billing fraud – not a viable qui tam opportunity,15,"The record provides only basic business information for a durable medical equipment (DME) company and contains no mention of Medicare, Medicaid, or any federal healthcare program billing. Without evidence of false claims, kickbacks, upcoding, or other fraudulent activity tied to a federal program, the case falls below the threshold for a qui tam filing. The lack of any documented billing patterns or dollar amounts further reduces viability.","Business name: 143 MEDICAL EQUIPMENT CO, a DME company; Specialty: oxygen equipment; No mention of Medicare or Medicaid billing; No documented claims, invoices, or financial data provided",,143 MEDICAL EQUIPMENT CO,,other
cms_leie_raw_row_5,70,Marketing firm with no evidence of federal healthcare billing – not a viable qui tam opportunity,5,"The entity is a marketing firm with no indication of Medicare or Medicaid billing activity. There is no evidence of false claims, kickbacks, or other fraud types, and the record contains only basic business information. Without federal program involvement, this case does not meet the criteria for a qui tam action.","Entity is a marketing firm, not a healthcare provider.; No mention of Medicare, Medicaid, or other federal health programs.; Record contains only basic business registration data.",,"149 BALLSTON AVENUE, LLC",,other
cms_leie_raw_row_6,71,Pharmacy excluded from Medicare Part B drug coverage in 2018 – no evidence of false claims activity,5,"The record only indicates that 184TH STREET PHARMACY CORP was excluded from Medicare Part B drug coverage on April 19, 2018. No billing data, claims, or allegations of fraudulent activity are provided, so the case lacks any basis for a qui tam action.",Business name: 184TH STREET PHARMACY CORP; NPI: 1922348218; Exclusion type: 1128a1 (Medicare Part B drug exclusion); Exclusion date: 2018‑04‑19; No claims or billing information provided,,184TH STREET PHARMACY CORP,,other
cms_leie_raw_row_7,72,Excluded pharmacy with no evidence of Medicare/Medicaid billing – not a viable qui tam opportunity,10,"The record identifies a pharmacy that is excluded from Medicare/Medicaid participation (EXCLTYPE 1128b5). No mention of federal program billing, no dollar amounts or fraud patterns are provided. The lack of any evidence of false claims makes this a low‑viability case.",Business name: 1951 Flatbush Avenue Pharmacy; Exclusion type 1128b5 indicates pharmacy exclusion from Medicare/Medicaid; No billing data or claims information provided,,1951 Flatbush Avenue Pharmacy,,other
cms_leie_raw_row_8,73,"Insufficient data to support a qui tam claim for 1ST COMMUNITY HEALTH CTR, LTD",20,"The record contains only basic provider information with no mention of Medicare/Medicaid billing, alleged false claims, or any documented fraudulent activity. Without evidence of federal program involvement or a pattern of misconduct, the case is not viable for filing.","Provider name: 1ST COMMUNITY HEALTH CTR, LTD; Location: Chicago, IL; No billing or claim data provided; No mention of Medicare/Medicaid or federal program participation",,"1ST COMMUNITY HEALTH CTR, LTD",,other
cms_leie_raw_row_9,74,Exclusion record for 1ST REHABILITATION OF PORT ST – no evidence of unfiled False Claims Act violations,5,"The record is a Medicare/Medicaid exclusion entry with no mention of billing activity, fraud allegations, or financial data. Without evidence of false claims or federal program involvement, the case is not viable for a qui tam filing.","Provider listed as excluded from Medicare/Medicaid (EXCLTYPE 1128b8) since 2002; No billing or claim data provided in the record; NPI is listed as 0000000000, indicating incomplete or placeholder data",,1ST REHABILITATION OF PORT ST,,other
cms_leie_raw_row_10,75,Exclusion record for 2001 Bath Avenue Pharmacy Inc. – no evidence of active Medicare billing fraud,15,"The record only indicates that the pharmacy was excluded from Medicare (EXCLTYPE 1128a1) in 2011, with no documentation of actual Medicare claims, billing patterns, or dollar amounts. Without evidence that the pharmacy continued to submit false claims after exclusion, the case is unlikely to meet the first‑to‑file requirement or provide a strong basis for a new qui tam action.",Pharmacy name: 2001 Bath Avenue Pharmacy Inc.; Excluded from Medicare under EXCLTYPE 1128a1 on 2011-08-18; No claim or billing data provided in the record,False Claims Act,2001 Bath Avenue Pharmacy Inc.,,other
cms_leie_raw_row_11,76,Pharmacy excluded from Medicare Part D – no evidence of unfiled False Claims Act violations,10,"The record only indicates that 2258 Pharmacy, Inc. was excluded from Medicare Part D under exclusion code 1128b8 in 2003, with no mention of billing practices, claims data, or fraudulent activity. Without evidence of false claims or federal program involvement beyond the exclusion, the case is not viable for a new qui tam filing.","Pharmacy name: 2258 Pharmacy, Inc.; Excluded from Medicare Part D (exclusion code 1128b8) as of July 20, 2003; No billing or claim data provided in the record",False Claims Act,"2258 Pharmacy, Inc.",,other
cms_leie_raw_row_12,77,No evidence of unfiled False Claims Act violations in the provided pharmacy record,10,"The record contains only basic business information for a pharmacy with no indication of Medicare/Medicaid billing, documented fraud, or financial data. Without evidence of false claims, kickbacks, or other violations, the case is not viable for a qui tam filing.","Business name: 227 NINTH AVENUE PHARMACY, INC; NPI: 0000000000; Exclusion type: 1128b5 (pharmacy); No billing or claim data provided; No mention of Medicare/Medicaid programs",,"227 NINTH AVENUE PHARMACY, INC",,other
cms_leie_raw_row_13,78,Pharmacy excluded from Medicare Part D participation – no evidence of false claims,10,"The record only indicates that 3839 Pharmacy, Inc. is a pharmacy excluded from Medicare Part D (EXCLTYPE 1128a1). No billing data, claims, or evidence of fraudulent activity is provided. Without federal program involvement or documented false claims, the case has minimal qui tam potential.","Business name: 3839 Pharmacy, Inc.; NPI: 0000000000; Exclusion type: 1128a1 (pharmacy excluded from Medicare Part D); No billing or claim information provided",,"3839 Pharmacy, Inc.",,other
cms_leie_raw_row_14,79,Excluded pharmacy with no evidence of federal program billing – not a viable qui tam opportunity,5,"The record indicates the pharmacy was excluded from Medicare/Medicaid in 1986 and contains no billing data or evidence of false claims. Without federal program involvement, the case falls below the threshold for a qui tam filing.","Business name: 54-26 Drug Corp, a pharmacy; NPI: 0000000000; Excluded type 1128b8 (Medicare/Medicaid exclusion); Exclusion date: December 4, 1986; No billing or claim data provided",False Claims Act,54-26 Drug Corp,,other
cms_leie_raw_row_15,80,Transportation company with no evidence of federal healthcare billing – not a viable qui tam opportunity,10,"The record identifies a transportation service provider with no mention of Medicare, Medicaid or other federal health programs. There is no indication of billing activity, fraud patterns, or financial amounts that would trigger a False Claims Act claim. The lack of federal program involvement and absence of any documented fraudulent behavior places this case in the low‑viability range.","Business type: transportation service, not a medical provider; No reference to Medicare/Medicaid billing or claims; NPI listed but no associated healthcare services; Exclusion type 1128a1 indicates a non‑healthcare entity",,"716 TRANSPORTATION, INC",,other
cms_leie_raw_row_16,81,Pharmacy excluded from Medicare participation; no evidence of false claims,5,"The record indicates a pharmacy that was excluded from Medicare participation (EXCLTYPE 1128a1) with no billing or claim data provided. Without evidence of Medicare/Medicaid claims, there is no basis for a False Claims Act claim.",Business name: 764 Franklin Ave Pharmacy Inc.; Exclusion type 1128a1 indicates Medicare exclusion; No claim or billing information present in the record,,764 Franklin Ave Pharmacy Inc.,,other
cms_leie_raw_row_17,82,Excluded pharmacy with no evidence of Medicare/Medicaid billing – not a viable qui tam opportunity,5,"The record indicates a pharmacy that is excluded from Medicare/Medicaid (EXCLTYPE 1128b4) and contains no billing data, dollar amounts, or evidence of fraudulent activity. Without federal program involvement or documented claims, the case is not actionable under the False Claims Act.",Pharmacy name: 882 E 180TH STREET DRUG CORP; NPI: 0000000000; Exclusion type 1128b4 indicates exclusion from Medicare/Medicaid; No billing or claim data provided,,882 E 180TH STREET DRUG CORP,,other
cms_leie_raw_row_18,83,Transportation company with no evidence of Medicare/Medicaid billing fraud,5,"The record identifies a transportation service provider (A & A Livery, Inc.) with no mention of healthcare billing, Medicare or Medicaid claims, or any fraudulent activity. Without federal program involvement or documented false claims, the case is not viable for a qui tam action.","Provider is a transportation company, not a medical provider.; No reference to Medicare or Medicaid billing.; Record contains only exclusion and waiver dates, no claim data.",,"A & A Livery, Inc.",,other
cms_leie_raw_row_19,84,Insufficient evidence to support a qui tam claim against A & A Medical Center Corp,15,"The record provides only basic provider identification and an exclusion type/date with no mention of Medicare/Medicaid billing, alleged false claims, or any financial data. Without evidence of federal program involvement or a documented pattern of fraud, the case is not viable for filing.",Provider name: A & A Medical Center Corp; Exclusion type 1128b8 with exclusion date 2001-07-19; No billing or claim data provided,,A & A Medical Center Corp,,other
cms_leie_raw_row_20,85,Pharmacy excluded from Medicare/Medicaid billing – no evidence of false claims,10,"The record only identifies a pharmacy that is excluded from Medicare/Medicaid billing under 1128(a)(1). No mention of federal program claims, billing amounts, or fraudulent activity. The lack of any Medicare/Medicaid involvement and absence of documented fraud places this case in the low‑viability range.",Business is a pharmacy (PHARMACY); Excluded from Medicare/Medicaid billing under 1128(a)(1); No claim or billing data provided; Record contains only basic business information,,"A & D PHARMACY, INC",,other
cms_leie_raw_row_21,86,Pharmacy excluded from Medicare; no federal program billing activity reported,5,"The record indicates that A & H LEE PHARMACY, INC is excluded from Medicare (EXCLTYPE 1128a1). No evidence of Medicare or Medicaid billing, no dollar amounts, and no indication of fraudulent activity. The lack of federal program involvement places the case in the lowest viability category.","Business name: A & H LEE PHARMACY, INC; Exclusion type 1128a1: exclusion from Medicare; No billing data or dollar amounts provided; Record contains only basic contact information",False Claims Act,"A & H LEE PHARMACY, INC",,other
cms_leie_raw_row_22,87,Excluded pharmacy supply company with no evidence of Medicare/Medicaid billing fraud,10,"The record indicates a pharmacy supply corporation that is excluded from Medicare (EXCLTYPE 1128a1). No billing data, claims information, or evidence of federal program involvement is provided. Without documentation of false claims or a pattern of fraud, the case does not meet criteria for a viable qui tam action.",Business is a pharmacy supply corporation (PHARMACY); Excluded from Medicare under EXCLTYPE 1128a1; No billing or claims data provided in the record,False Claims Act,A & H VITAMINS SUPPLY CORP,,other
cms_leie_raw_row_23,88,DME company with no evidence of Medicare/Medicaid billing or fraud,20,"The record provides only basic business information for a DME company with no mention of Medicare, Medicaid, or any billing activity. Without evidence of federal program involvement or fraudulent conduct, the case is unlikely to support a qui tam action.","Business name: A & I HEALTH AIDS; Industry: DME company specializing in orthotics; NPI: 0000000000; Location: Oceanside, NY; No Medicare/Medicaid billing data provided",,A & I HEALTH AIDS,,other
cms_leie_raw_row_24,89,Insufficient evidence to support a qui tam claim for A & J Medical Corp,15,"The record contains only basic provider identification and exclusion dates with no mention of Medicare/Medicaid billing, alleged false claims, or any pattern of fraudulent activity. Without evidence of federal program involvement or documented billing misconduct, the case is not viable for a qui tam filing.",Provider name: A & J Medical Corp; Business type: Clinic; NPI: 0000000000; Exclusion type: 1128b8 (likely a Medicare exclusion); No billing or claim data provided,,A & J Medical Corp,,other
cms_leie_raw_row_25,90,Home health agency excluded from Medicare; no evidence of unfiled fraud,20,"The record only indicates that A & M CARE, INC is a home health agency excluded from Medicare (EXCLTYPE 1128a1). No billing data, no mention of Medicare/Medicaid claims, or any fraudulent activity is provided. The exclusion itself does not constitute a False Claims Act violation and offers no basis for a qui tam action.","Business name: A & M CARE, INC; Type: Home Health Agency; NPI: 0000000000; Exclusion type: 1128a1 (Medicare exclusion); No claim or billing information provided",,"A & M CARE, INC",,other
cms_leie_raw_row_26,91,Excluded DME supplier with no evidence of fraudulent billing – not a viable qui tam opportunity,5,"The record only identifies a DME company that was excluded from Medicare (EXCLTYPE 1128b8) with no mention of billing activity, claims data, or alleged fraud. Without evidence of false claims or federal program involvement, the case does not meet the threshold for a qui tam filing.","Company name: A & Y MEDICAL SUPPLY, INC; Business type: DME company; Medicare exclusion code 1128b8 effective May 18, 2017; No billing or claim data provided",,"A & Y MEDICAL SUPPLY, INC",,other
cms_leie_raw_row_27,92,DME company excluded from Medicare; no evidence of false claims activity,5,"The record indicates that A & A Orthopedics, Inc. is a DME company excluded from Medicare (EXCLTYPE 1128b8). No billing data, claims records, or allegations of fraudulent activity are provided. Without evidence of Medicare/Medicaid involvement or documented false claims, the case is not viable for a qui tam filing.",Business is a DME company; Excluded from Medicare (EXCLTYPE 1128b8); No claims or billing information provided; No mention of Medicare/Medicaid services,,"A AND A ORTHOPEDICS, INC",,other
cms_leie_raw_row_28,93,Insufficient evidence of federal program fraud for A BACK & ACCIDENT CHIROPRACTIC,15,"The record provides only basic provider information with no indication of Medicare/Medicaid billing, documented fraud patterns, or dollar amounts. Without evidence of federal program involvement or a clear fraudulent scheme, the case is unlikely to meet the threshold for a viable qui tam filing.","Provider is a chiropractic practice located in Springfield, MO.; No mention of Medicare or Medicaid billing activities.; Record contains only basic registration data (NPI, address, exclusion type).",,A BACK & ACCIDENT CHIROPRACTIC,,other
cms_leie_raw_row_29,94,Chiropractic practice excluded from Medicare – no federal program involvement,5,"The provider is listed as excluded from Medicare (EXCLTYPE 1128b8), indicating no billing to federal health programs. Without evidence of Medicare/Medicaid claims, the case cannot support a False Claims Act claim and is not viable for qui tam.",Provider: A BASTECKI CHIROPRACTIC; Excluded from Medicare (EXCLTYPE 1128b8); No mention of billing or claims; NPI: 0000000000,,A BASTECKI CHIROPRACTIC,,other
cms_leie_raw_row_30,95,"Insufficient evidence to support a qui tam claim against A Caring Alternative, Inc.",15,"The record provides only basic provider information (name, NPI, address) and an exclusion type/date. No mention of Medicare/Medicaid billing, fraudulent activity, dollar amounts, or patterns. Without evidence of false claims or federal program involvement, the case is not viable for a qui tam filing.","Provider: A Caring Alternative, Inc.; NPI: 1275600959; Specialty: Home Health Agency; Exclusion type/date: 1128a1 / 20130320",,"A Caring Alternative, Inc.",,other
cms_leie_raw_row_31,96,Dental practice excluded from Medicare/Medicaid for fraud – no evidence of current false claims,5,"The record only indicates that the provider was excluded from Medicare/Medicaid (exclusion type 1128a1) with no mention of current billing activity, specific dollar amounts, or a pattern of false claims. Without evidence of ongoing federal program involvement or documented fraudulent billing, the case is unlikely to support a new qui tam action.","Provider is a dental practice located in Allen Park, MI; NPI listed as 0000000000 (placeholder); Exclusion type 1128a1 indicates prior exclusion from Medicare/Medicaid for fraud or abuse; No billing records, dates of reinduction or waiver provided",False Claims Act,"A DENTAL CENTER, P C",,other
cms_leie_raw_row_32,97,Dental practice excluded from Medicare in 2004 with no evidence of recent federal billing activity,20,"The record indicates a dental practice that was excluded from Medicare in 2004 (EXCLTYPE 1128a1). No recent billing data, dates of re‑induction or waiver are present, and there is no mention of Medicare/Medicaid claims. The exclusion predates the 6‑year statute of limitations for most potential false claim allegations, and dental services are largely outside Medicare’s coverage. Therefore the case is unlikely to support a new qui tam filing.",Dental practice (EXCLTYPE 1128a1) excluded from Medicare on 2004-07-20; No re‑induction or waiver dates recorded; NPI listed but no claim data provided,False Claims Act,"A DENTAL CENTER, P C",,other
cms_leie_raw_row_33,98,Pharmacy excluded from Medicare/Medicaid in 2017 – no current federal program billing activity,15,"The pharmacy is listed as an excluded entity (1128b8) with an exclusion date of 2017, indicating it is not authorized to bill Medicare or Medicaid. Without evidence of federal program billing, the case lacks a False Claims Act basis and is likely outside the statute of limitations for any prior activity.","Business name: A FAIR DEAL PHARMACY, INC; Exclusion type 1128b8 (pharmacy) with exclusion date 2017-05-18; No indication of Medicare/Medicaid billing or claims data",False Claims Act,"A FAIR DEAL PHARMACY, INC",,other
cms_leie_raw_row_34,99,No evidence of federal program billing or fraud in the provided record,20,"The record contains only basic provider information with no mention of Medicare/Medicaid billing, specific claims data, or any alleged fraudulent activity. Without evidence of federal program involvement or a pattern of false claims, the case is unlikely to meet the threshold for a viable qui tam filing.","Provider name: A FAMILY CARE CENTER; Location: 1775 ACCESS RD, COVINGTON, GA 30014; NPI: 0000000000; No billing or claim data provided",,A FAMILY CARE CENTER,,other
cms_leie_raw_row_35,100,Transportation company with no evidence of federal healthcare program billing – not a viable qui tam opportunity,5,"The record identifies a transportation business (A G Enterprises, Inc.) with no mention of Medicare/Medicaid billing or any healthcare services. Without federal program involvement, the case falls into the ""NOT VIABLE"" category per the scoring framework.","Business type: Transportation company, not a healthcare provider.; No reference to Medicare, Medicaid, or any federal health program.; Record contains only basic company information (NPI, address).",,"A G Enterprises, Inc.",,other
